GSK573719/GW642444 62.5/25

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

CompletedNCT01316913

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2011-03-31End: 2012-04-30Updated: 2017-04-04

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

CompletedNCT01316900

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2011-03-01End: 2012-04-24Updated: 2018-01-24

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

CompletedNCT01323660

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2011-03-16End: 2012-07-16Updated: 2018-02-15

Related Papers

Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.

2016-10-2838 citations

Treatment effect of umeclidinium/vilanterol and tiotropium on SGRQ sub-domains

2016-09-01

P144 A comparison of shuttle walking test endpoints in exercise studies in patients with COPD: Abstract P144 Table 1

Thorax2015-11-12

A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease.

2015-10-315 citations

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.

2014-05-14185 citations